NO20072664L - Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser - Google Patents

Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser

Info

Publication number: NO20072664L
Authority: NO; Norway
Prior art keywords: proliferative; neurological; applications; treatment; inflammatory disorders
Prior art date: 2004-12-20

Application number

NO20072664A

Other languages

English (en)

Norwegian (no)

Inventor

Kevin Pong

Edmund Idris Graziani

Jerauld Skotnicki

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-20

Filing date

2007-05-25

Publication date

2007-06-25

2007-05-25 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-06-25 Publication of NO20072664L publication Critical patent/NO20072664L/no

Links

208000027866 inflammatory disease Diseases 0.000 title abstract 2
230000002062 proliferating effect Effects 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000012902 Nervous system disease Diseases 0.000 abstract 2
201000009030 Carcinoma Diseases 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000009956 adenocarcinoma Diseases 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000003018 neuroregenerative effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20072664A 2004-12-20 2007-05-25 Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser NO20072664L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63766604P	2004-12-20	2004-12-20
PCT/US2005/045551 WO2006068932A2 (en)	2004-12-20	2005-12-15	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Publications (1)

Publication Number	Publication Date
NO20072664L true NO20072664L (no)	2007-06-25

Family

ID=36087657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072664A NO20072664L (no)	2004-12-20	2007-05-25	Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser

Country Status (26)

Country	Link
US (5)	US7276498B2 (de)
EP (1)	EP1828202B1 (de)
JP (1)	JP5094406B2 (de)
KR (1)	KR20070090913A (de)
CN (1)	CN101084227B (de)
AR (1)	AR052269A1 (de)
AT (1)	ATE549342T1 (de)
AU (1)	AU2005319454B2 (de)
BR (1)	BRPI0519495A2 (de)
CA (1)	CA2590155A1 (de)
CR (1)	CR9148A (de)
DK (1)	DK1828202T3 (de)
ES (1)	ES2380779T3 (de)
GT (1)	GT200500368A (de)
HN (1)	HN2005035605A (de)
IL (1)	IL183664A (de)
MX (1)	MX2007007408A (de)
NI (1)	NI200700157A (de)
NO (1)	NO20072664L (de)
NZ (1)	NZ574663A (de)
PE (1)	PE20060765A1 (de)
RU (1)	RU2394036C2 (de)
SG (1)	SG158143A1 (de)
TW (1)	TW200628152A (de)
UA (1)	UA94034C2 (de)
WO (1)	WO2006068932A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1553940E (pt)	2002-07-30	2008-05-09	Wyeth Corp	Formulações parentéricas contendo um hidroxi-éster de rapamicina
CA2556622A1 (en) *	2004-03-02	2005-09-15	Wyeth	Macrolides and methods for producing same
JP2008501342A (ja) *	2004-06-03	2008-01-24	ワイス	複合ポリケチドを生成するための生合成遺伝子クラスター
RU2394036C2 (ru) *	2004-12-20	2010-07-10	Вайет	Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний
MX2007007409A (es) *	2004-12-20	2007-07-12	Wyeth Corp	Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
TW200736603A (en) *	2005-12-07	2007-10-01	Wyeth Corp	Methods for preparing crystalline rapamycin and measuring crystallinity of rapamycin compounds using differential scanning calorimetry
TW200804399A (en) *	2005-12-07	2008-01-16	Wyeth Corp	Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
WO2007067565A1 (en) *	2005-12-07	2007-06-14	Wyeth	Process for the preparation of purified crystalline cci-779
AR059738A1 (es)	2006-03-07	2008-04-23	Wyeth Corp	Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
TW200824713A (en) *	2006-10-18	2008-06-16	Wyeth Corp	Processes for the synthesis of individual isomers of mono-PEG CCI-779
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20100196355A1 (en) *	2007-01-29	2010-08-05	Wyeth	Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
KR101666228B1 (ko)	2007-09-28	2016-10-13	인트렉손 코포레이션	생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US8653045B2 (en) *	2008-02-05	2014-02-18	The Johns Hopkins University	Induction of thyroid iodide-handling gene expression in human cancers
US20090209527A1 (en) *	2008-02-19	2009-08-20	Wyeth	Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
ES2685947T3 (es)	2009-04-10	2018-10-15	Haiyan Qi	Agentes antienvejecimiento
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
CN103038343A (zh)	2010-03-23	2013-04-10	英特瑞克斯顿股份有限公司	条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
ES2372077B2 (es) *	2010-06-24	2012-05-18	Universidad De Sevilla	Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (de) *	2010-10-29	2012-05-02	Fondazione Telethon	Autophagieregulierer und ihre Verwendungen beim der Behandlung von Kollagen-VI-gestörten Muskeldystrophien
WO2012122025A2 (en)	2011-03-04	2012-09-13	Intrexon Corporation	Vectors conditionally expressing protein
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
EP2906214A1 (de)	2012-10-12	2015-08-19	The Board of Regents of The University of Texas System	Verwendung von mtor-hemmern zur behandlung von vaskulären kognitiven störungen
ITMI20122065A1 (it) *	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
GB2538747B (en) *	2015-05-27	2022-04-13	Airbus Operations Ltd	A measuring apparatus for measuring properties of a surface
WO2016205334A1 (en)	2015-06-16	2016-12-22	Vascular Strategies Llc	Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
UY37343A (es)	2016-07-25	2018-02-28	Intrexon Corp	Control del fenotipo en plantas
IL266358B2 (en)	2016-11-09	2025-10-01	Precigen Inc	Constructs for Prataxin Expression
EP3624863B1 (de)	2017-05-15	2021-04-14	C.R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2020076738A2 (en) *	2018-10-12	2020-04-16	Bellicum Pharmaceuticals, Inc	Protein-binding compounds
CN113226389B (zh)	2018-11-14	2022-11-08	乐通公司	在经改性设备表面上具有药物洗脱涂层的医疗设备
EA202191983A1 (ru)	2019-01-22	2021-12-01	Аеовиан Фармасьютикалз, Инк.	МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
EP4185590A2 (de) *	2020-07-21	2023-05-31	Aeovian Pharmaceuticals, Inc.	Mtorc1-modulatoren und verwendungen davon
CN115887452A (zh) *	2022-01-27	2023-04-04	中以海德人工智能药物研发股份有限公司	雷帕霉素在治疗或预防乙型肝炎中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1445742A1 (de)	1963-11-06	1968-12-19	Bayer Ag	Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de)	1965-06-21	1969-12-11	Bayer Ag	Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
GB1325047A (en)	1969-08-11	1973-08-01	Ciba Geigy Ag	Rifamycin compounds and processes for their manufacture
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en)	1973-04-05	1975-08-19	Lepetit Spa	3-formylrifamycin azines
US3905981A (en)	1973-10-12	1975-09-16	Research Corp	N-dealkylation of tertiary amines
US4127720A (en)	1977-09-21	1978-11-28	Bristol-Myers Company	Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja)	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
JPH05507915A (ja)	1990-06-11	1993-11-11	藤沢薬品工業株式会社	特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
DE4021404A1 (de)	1990-07-05	1992-01-09	Sandoz Ag	Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
GB2249027A (en)	1990-10-23	1992-04-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds for hepatic failure
WO1992013862A1 (en)	1991-02-05	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Lactone compounds
US5604294A (en)	1991-09-05	1997-02-18	Luly; Jay R.	Macrocyclic immunomodulators
WO1993004680A1 (en)	1991-09-05	1993-03-18	Abbott Laboratories	Macrocyclic immunomodulators
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US7279561B1 (en)	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
ES2176245T3 (es)	1993-04-23	2002-12-01	Wyeth Corp	Anticuerpos de ramapicinas de ciclo abierto.
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
US5525610A (en)	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
KR100400620B1 (ko) *	1995-06-09	2004-02-18	노파르티스 아게	라파마이신유도체
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5717092A (en)	1996-03-29	1998-02-10	Vertex Pharmaceuticals Inc.	Compounds with improved multi-drug resistance activity
US5780484A (en)	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en)	1998-06-03	2001-02-13	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
AU761083B2 (en)	1998-06-03	2003-05-29	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
CA2340700A1 (en)	1998-08-17	2000-02-24	American Home Products Corporation	Photocyclized rapamycins
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
AU2478500A (en)	1998-12-08	2000-06-26	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6441017B1 (en)	1999-09-09	2002-08-27	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6569867B2 (en)	1999-10-01	2003-05-27	Kosan Biosciences, Inc.	Polyketide derivatives
DE60033965T2 (de)	1999-10-29	2008-01-10	Kosan Biosciences, Inc., Hayward	Rapamycin analoge
WO2001087884A2 (en)	2000-05-17	2001-11-22	Kosan Biosciences, Inc.	Polyketide derivatives
MXPA04001523A (es)	2001-08-22	2004-05-31	Wyeth Corp	Dialdehidos de rapamicina.
DE60206512T2 (de)	2001-08-22	2006-06-22	Wyeth	Rapamycin 29-enole
ES2544624T3 (es)	2002-07-16	2015-09-02	Buck Institute For Research On Aging	Producción de policétidos
DE102004049700B4 (de)	2004-10-12	2007-10-18	Aircabin Gmbh	Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
RU2394036C2 (ru) *	2004-12-20	2010-07-10	Вайет	Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний
MX2007007409A (es) *	2004-12-20	2007-07-12	Wyeth Corp	Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
AR059738A1 (es) *	2006-03-07	2008-04-23	Wyeth Corp	Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

2005
- 2005-12-15 RU RU2007119584/04A patent/RU2394036C2/ru not_active IP Right Cessation
- 2005-12-15 MX MX2007007408A patent/MX2007007408A/es active IP Right Grant
- 2005-12-15 SG SG200908383-3A patent/SG158143A1/en unknown
- 2005-12-15 US US11/300,839 patent/US7276498B2/en not_active Expired - Fee Related
- 2005-12-15 WO PCT/US2005/045551 patent/WO2006068932A2/en not_active Ceased
- 2005-12-15 NZ NZ574663A patent/NZ574663A/en not_active IP Right Cessation
- 2005-12-15 EP EP05849447A patent/EP1828202B1/de not_active Expired - Lifetime
- 2005-12-15 CA CA002590155A patent/CA2590155A1/en not_active Abandoned
- 2005-12-15 AR ARP050105290A patent/AR052269A1/es not_active Application Discontinuation
- 2005-12-15 AU AU2005319454A patent/AU2005319454B2/en not_active Expired - Fee Related
- 2005-12-15 ES ES05849447T patent/ES2380779T3/es not_active Expired - Lifetime
- 2005-12-15 DK DK05849447.7T patent/DK1828202T3/da active
- 2005-12-15 JP JP2007546925A patent/JP5094406B2/ja not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519495-4A patent/BRPI0519495A2/pt not_active IP Right Cessation
- 2005-12-15 AT AT05849447T patent/ATE549342T1/de active
- 2005-12-15 HN HN2005035605A patent/HN2005035605A/es unknown
- 2005-12-15 UA UAA200706849A patent/UA94034C2/ru unknown
- 2005-12-15 TW TW094144448A patent/TW200628152A/zh unknown
- 2005-12-15 CN CN2005800437154A patent/CN101084227B/zh not_active Expired - Fee Related
- 2005-12-15 KR KR1020077013082A patent/KR20070090913A/ko not_active Ceased
- 2005-12-15 PE PE2005001466A patent/PE20060765A1/es not_active Application Discontinuation
- 2005-12-15 GT GT200500368A patent/GT200500368A/es unknown
2007
- 2007-01-26 US US11/698,504 patent/US7560457B2/en not_active Expired - Fee Related
- 2007-05-24 CR CR9148A patent/CR9148A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072664A patent/NO20072664L/no not_active Application Discontinuation
- 2007-06-04 IL IL183664A patent/IL183664A/en not_active IP Right Cessation
- 2007-06-18 NI NI200700157A patent/NI200700157A/es unknown
- 2007-08-14 US US11/893,090 patent/US7470682B2/en not_active Expired - Fee Related
2008
- 2008-11-24 US US12/276,668 patent/US20090203682A1/en not_active Abandoned
2009
- 2009-06-09 US US12/481,211 patent/US7795252B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20070090913A (ko)	2007-09-06
US20090239855A1 (en)	2009-09-24
HK1108442A1 (en)	2008-05-09
IL183664A0 (en)	2007-09-20
CR9148A (es)	2007-11-23
US7470682B2 (en)	2008-12-30
EP1828202B1 (de)	2012-03-14
SG158143A1 (en)	2010-01-29
US7795252B2 (en)	2010-09-14
US7560457B2 (en)	2009-07-14
WO2006068932A2 (en)	2006-06-29
US20090203682A1 (en)	2009-08-13
JP2008524240A (ja)	2008-07-10
TW200628152A (en)	2006-08-16
US7276498B2 (en)	2007-10-02
HN2005035605A (es)	2010-08-05
MX2007007408A (es)	2007-07-12
US20070142423A1 (en)	2007-06-21
JP5094406B2 (ja)	2012-12-12
CN101084227B (zh)	2011-11-16
US20060135549A1 (en)	2006-06-22
PE20060765A1 (es)	2006-10-02
ES2380779T3 (es)	2012-05-18
AU2005319454A1 (en)	2006-06-29
BRPI0519495A2 (pt)	2009-02-03
NI200700157A (es)	2008-04-21
WO2006068932A3 (en)	2006-10-19
GT200500368A (es)	2006-07-13
UA94034C2 (ru)	2011-04-11
NZ574663A (en)	2010-05-28
EP1828202A2 (de)	2007-09-05
DK1828202T3 (da)	2012-05-07
AU2005319454B2 (en)	2012-08-09
AR052269A1 (es)	2007-03-07
CA2590155A1 (en)	2006-06-29
IL183664A (en)	2012-06-28
RU2394036C2 (ru)	2010-07-10
RU2007119584A (ru)	2009-01-27
ATE549342T1 (de)	2012-03-15
CN101084227A (zh)	2007-12-05
US20080004264A1 (en)	2008-01-03

Legal Events

Date	Code	Title	Description
2014-07-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072664L (no)	2007-06-25	Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser
NO20072665L (no)	2007-09-07	Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
CY2013022I1 (el)	2020-05-29	Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
EA200900663A1 (ru)	2009-12-30	Лечение синдрома "сухого глаза"
BR9913319A (pt)	2001-05-22	Composições e métodos para tratamento de doenças mitocondriais
NO20070247L (no)	2007-02-13	Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
DK1955700T3 (da)	2011-05-23	Terapeutisk behandling af androgenreceptor-betingede lidelser
AR028824A1 (es)	2003-05-28	Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ECSP034809A (es)	2004-02-26	Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
PA8571001A1 (es)	2003-12-10	2-(2,6-diclorofenil)-diarilimidazoles
ATE361288T1 (de)	2007-05-15	N-(3,-dimethylindolin-6-yl)ä2-ä(4-
EA200601648A1 (ru)	2007-04-27	Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
ATE384058T1 (de)	2008-02-15	Thiazolderivate
ATE427759T1 (de)	2009-04-15	Behandlung von fettsucht und verbundenen erkrankungen
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0215151A (pt)	2004-10-19	Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
EA200301142A1 (ru)	2004-02-26	Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EP1251126A3 (de)	2002-10-30	Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
PL1891029T3 (pl)	2010-06-30	Związki organiczne do leczenia stanów zapalnych lub alergicznych
WO2004074243A3 (en)	2004-12-02	Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
BRPI0508051A (pt)	2007-07-17	derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
ECSP045156A (es)	2004-07-23	Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
DE60014136D1 (de)	2004-10-28	Sapogenin derivate zur behandlung von kognitiven störungen
PT1562954E (pt)	2006-07-31	Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
CR8696A (es)	2007-08-28	Beta-carbolinas utiles para tratar enfermedades inflamatorias